Vaccine combination therapy for metastatic pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new tumor vaccine combined with a standard chemotherapy regimen (AG) for people with metastatic pancreatic cancer. It aims to see if the combination is safe and helps the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic pancreatic cancer that cannot be removed by surgery.
- You have not had any previous chemotherapy or other systemic treatment for advanced pancreatic cancer.
- You are in fairly good physical health (able to do daily activities with little or no help).
- Your liver, kidney, and blood cell counts are within certain ranges.
- You do not have an autoimmune disease or condition that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a new combination of treatments for people with advanced pancreatic cancer that has spread to the liver or lungs. It includes a cancer vaccine, two chemotherapy drugs, an immunotherapy drug, and a heat-based therapy to see if it can help shrink tumors and improve outcomes.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with standard chemotherapy after surgery for pancreatic cancer. The goal is to see if the vaccine can help prevent the cancer from coming back.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This early-stage trial tests a personalized immune “vaccine” made from dendritic cells, given alongside standard chemotherapy for pancreatic cancer that may be removable by surgery (resectable or borderline resectable). If it works, it may help your immune system better recognize and attack the cancer around the time of treatment.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.